Protein phosphatase 2A regulates senescence and immunogenicity in medulloblastoma models
Journal of Clinical Investigation · 2026
DOI: 10.1172/jci196753 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Winson S Ho und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, and. Hauptthemen laut MEDLINE: Medulloblastoma, Cellular Senescence, Cerebellar Neoplasms, Neoplasm Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, National Institutes of Health, Meghan Rose Bradley Foundation.
Abstract (Originalsprache)
Medulloblastoma (MB) is the most common malignant pediatric brain tumor. Current therapies are associated with substantial morbidity, and prognosis remains poor in high-risk subgroups, particularly those with TP53 mutations or relapsed disease. Cellular senescence is a tumor-suppressive program implicated in MB, but its role in antitumor immunity remains incompletely understood. We found that protein phosphatase 2A (PP2A) regulated immunogenic senescence in MB. Genetic ablation of the PP2A catalytic subunit PP2Ac or depletion of the regulatory subunit PP2A-B56α induced senescence in MB models. PP2Ac-deficient senescent cells exhibited increased MHC class I expression and enhanced immunogenicity. In syngeneic orthotopic models, PP2Ac loss prolonged survival in an immune- and CD8 + T cell–dependent manner. Analysis of patient datasets showed that senescence-associated gene signatures correlated with improved survival. Single-cell transcriptomic analysis further revealed that senescent MB cells were heterogeneous and that reduced PP2A activity was associated with an immunogenic senescence state. Because the PP2A inhibitor LB-100 has limited potency and off-target effects, we developed a lipid nanoparticle (LNP) platform to deliver siRNA targeting PPP2CA . LNP–small-interfering PP2Ac efficiently silenced PP2Ac in vitro and, when delivered locally in vivo, prolonged survival in a CD8 + T cell–dependent manner. Together, these findings identify PP2A as a regulator of immunogenic senescence in MB and support PP2Ac targeting as a therapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurological Surgery, and.
- Helen Diller Comprehensive Cancer Center, UCSF, San Francisco, California, USA.
- Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Department of Neurological Surgery, Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Förderung
- NINDS NIH HHS
- National Institutes of Health
- Meghan Rose Bradley Foundation
- Matthew Larson Foundation
- Alex’s Lemonade Stand Foundation
Zitieren
APA
Ho, W. S., Mondal, I., Liu, J., Sun, R., Huo, J., Gao, C., Das, O., Tieu, D., Sun, J., Lin, H., Zhang, P., Yu, J., & Lu, R. O. (2026). Protein phosphatase 2A regulates senescence and immunogenicity in medulloblastoma models. Journal of Clinical Investigation. https://doi.org/10.1172/jci196753
Vancouver
Ho WS, Mondal I, Liu J, Sun R, Huo J, Gao C, et al. Protein phosphatase 2A regulates senescence and immunogenicity in medulloblastoma models. Journal of Clinical Investigation. 2026. doi:10.1172/jci196753
BibTeX
@article{Ho2026,
author = {Ho, Winson S and Mondal, Isha and Liu, Jingjing and Sun, Raymond and Huo, Jiawei and Gao, Chao and Das, Oishika and Tieu, Daren and Sun, Jingqi and Lin, Hanchen and Zhang, Peng and Yu, Jiyang and Lu, Rongze Olivia},
title = {Protein phosphatase 2A regulates senescence and immunogenicity in medulloblastoma models},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci196753}
}
EUVIMED